Logo image of CYRX

CRYOPORT INC (CYRX) Stock Fundamental Analysis

NASDAQ:CYRX - Nasdaq - US2290503075 - Common Stock - Currency: USD

6.04  -0.18 (-2.89%)

After market: 6.04 0 (0%)

Fundamental Rating

2

Overall CYRX gets a fundamental rating of 2 out of 10. We evaluated CYRX against 56 industry peers in the Life Sciences Tools & Services industry. While CYRX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CYRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CYRX has reported negative net income.
CYRX had a negative operating cash flow in the past year.
In the past 5 years CYRX always reported negative net income.
In the past 5 years CYRX reported 4 times negative operating cash flow.
CYRX Yearly Net Income VS EBIT VS OCF VS FCFCYRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

CYRX has a Return On Assets of -16.55%. This is comparable to the rest of the industry: CYRX outperforms 46.43% of its industry peers.
CYRX's Return On Equity of -29.05% is in line compared to the rest of the industry. CYRX outperforms 42.86% of its industry peers.
Industry RankSector Rank
ROA -16.55%
ROE -29.05%
ROIC N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
CYRX Yearly ROA, ROE, ROICCYRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

CYRX's Gross Margin of 44.92% is in line compared to the rest of the industry. CYRX outperforms 46.43% of its industry peers.
In the last couple of years the Gross Margin of CYRX has declined.
CYRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
CYRX Yearly Profit, Operating, Gross MarginsCYRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

CYRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CYRX has been increased compared to 5 years ago.
CYRX has a better debt/assets ratio than last year.
CYRX Yearly Shares OutstandingCYRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CYRX Yearly Total Debt VS Total AssetsCYRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.29, we must say that CYRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.29, CYRX is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
CYRX has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
CYRX has a worse Debt to Equity ratio (0.47) than 60.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Altman-Z -0.29
ROIC/WACCN/A
WACC8.2%
CYRX Yearly LT Debt VS Equity VS FCFCYRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CYRX has a Current Ratio of 5.56. This indicates that CYRX is financially healthy and has no problem in meeting its short term obligations.
CYRX has a better Current ratio (5.56) than 75.00% of its industry peers.
A Quick Ratio of 5.24 indicates that CYRX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 5.24, CYRX belongs to the best of the industry, outperforming 82.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.56
Quick Ratio 5.24
CYRX Yearly Current Assets VS Current LiabilitesCYRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 59.11% over the past year.
Looking at the last year, CYRX shows a decrease in Revenue. The Revenue has decreased by -4.53% in the last year.
CYRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 46.45% yearly.
EPS 1Y (TTM)59.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.88%
Revenue 1Y (TTM)-4.53%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-24.82%

3.2 Future

The Earnings Per Share is expected to grow by 8.05% on average over the next years. This is quite good.
CYRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.78% yearly.
EPS Next Y8.44%
EPS Next 2Y11.77%
EPS Next 3Y10.02%
EPS Next 5Y8.05%
Revenue Next Year-21.28%
Revenue Next 2Y-7.19%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.78%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CYRX Yearly Revenue VS EstimatesCYRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
CYRX Yearly EPS VS EstimatesCYRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CYRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYRX Price Earnings VS Forward Price EarningsCYRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYRX Per share dataCYRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.77%
EPS Next 3Y10.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRYOPORT INC

NASDAQ:CYRX (5/23/2025, 9:25:16 PM)

After market: 6.04 0 (0%)

6.04

-0.18 (-2.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners103.11%
Inst Owner Change-2.96%
Ins Owners2.69%
Ins Owner Change9.77%
Market Cap302.85M
Analysts78.75
Price Target11.39 (88.58%)
Short Float %5.47%
Short Ratio4.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.32%
Min EPS beat(2)-40.53%
Max EPS beat(2)13.89%
EPS beat(4)3
Avg EPS beat(4)23.57%
Min EPS beat(4)-40.53%
Max EPS beat(4)93.29%
EPS beat(8)4
Avg EPS beat(8)-42.43%
EPS beat(12)5
Avg EPS beat(12)-33.13%
EPS beat(16)6
Avg EPS beat(16)-30.33%
Revenue beat(2)0
Avg Revenue beat(2)-2.8%
Min Revenue beat(2)-5.29%
Max Revenue beat(2)-0.31%
Revenue beat(4)0
Avg Revenue beat(4)-3%
Min Revenue beat(4)-5.29%
Max Revenue beat(4)-0.31%
Revenue beat(8)0
Avg Revenue beat(8)-3.87%
Revenue beat(12)1
Avg Revenue beat(12)-4.07%
Revenue beat(16)3
Avg Revenue beat(16)-2.92%
PT rev (1m)0%
PT rev (3m)-1.18%
EPS NQ rev (1m)14.17%
EPS NQ rev (3m)-1.43%
EPS NY rev (1m)12.16%
EPS NY rev (3m)-3.11%
Revenue NQ rev (1m)-17.99%
Revenue NQ rev (3m)-27.73%
Revenue NY rev (1m)-18.67%
Revenue NY rev (3m)-26.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.41
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 1.3
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS4.28
BVpS7.95
TBVpS4.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.55%
ROE -29.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.92%
FCFM N/A
ROA(3y)-11.01%
ROA(5y)-14.42%
ROE(3y)-20.23%
ROE(5y)-24.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y-3.2%
F-Score4
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.52%
Cap/Sales 9.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.56
Quick Ratio 5.24
Altman-Z -0.29
F-Score4
WACC8.2%
ROIC/WACCN/A
Cap/Depr(3y)112.93%
Cap/Depr(5y)112.05%
Cap/Sales(3y)12.92%
Cap/Sales(5y)12.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.88%
EPS Next Y8.44%
EPS Next 2Y11.77%
EPS Next 3Y10.02%
EPS Next 5Y8.05%
Revenue 1Y (TTM)-4.53%
Revenue growth 3Y0.86%
Revenue growth 5Y46.45%
Sales Q2Q%-24.82%
Revenue Next Year-21.28%
Revenue Next 2Y-7.19%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.78%
EBIT growth 1Y28.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.61%
EBIT Next 3Y26.94%
EBIT Next 5Y16.83%
FCF growth 1Y-29.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4450%
OCF growth 3YN/A
OCF growth 5YN/A